Table 2.
Cancer-specific survival analysis (n = 155).
| CSS, n = 155 Variables |
Kaplan-Meier Survival Analysis, CSS, n = 155 Patients |
UNIVARIATE Cox Regression | MULTIVARIATE Cox Regression | ||||
|---|---|---|---|---|---|---|---|
| X2 | p-Value | CSS (Range) | HR (IC 95%) | p-Value | HR (IC 95%) | p-Value | |
| Age ≥ 65 years (vs. <65 years) | 1.9 | 0.167 | 68.5 (60.0–77.0) vs. 89.5 (82.2–96.9) | 1.4 (0.8–2.5) | 0.206 | - | - |
| FIGO stage III (vs. stage I–II) * | 4.5 | 0.034 | 78.0 (66.8–89.3) vs. 75.7 (70.4–81.1) | 2.0 (1.04–3.9) | 0.038 | 2.2 (1.1–4.3) | 0.021 |
| Tumor grade 3 (vs. grade 1–2) | 1.6 | 0.206 | 69.8 (63.3–76.3) vs. 89.4 (79.7–99.1) | 1.1 (0.6–2.1) | 0.648 | - | - |
| Endometrioid histology (vs. other histology) | 0.2 | 0.656 | 86.2 (78.1–94.3) vs. 70.1 (62.9–78.9) | 0.8 (0.4–1.4) | 0.391 | - | - |
| NLR ≥ 2.2 (vs. <2.2) |
4.3 | 0.038 | 68.9 (62.0–75.7) vs. 93.0 (84.0–102.1) | 1.4 (0.8–2.5) | 0.285 | - | - |
| SII ≥1100 (vs. <1100) |
4.1 | 0.042 | 63.2 (49.5–76.9) vs. 87.7 (80.9–94.5) | 1.4 (0.7–2.7) | 0.352 | - | - |
| MLR ≥ 0.18 (vs. <0.18) |
6.0 | 0.014 | 60.5 (47.0–74.1) vs. 79.4 (74.7–88.6) | 4.9 (1.2–20.8) | 0.027 | 5.4 (1.3–22.7) | 0.020 |
| Lymphocytes <1.0 (vs. ≥1.0) |
11.1 | 0.001 | 39.2 (21.7–56.6) vs. 87.6 (81.2–94.1) | 4.0 (1.7–9.7) | 0.002 | 5.0 (2.0–12.5) | 0.001 |
* FIGO stage III in separate Cox multivariate models: HR = 2.4 (IC 95% 1.2–4.7, p = 0.014) for lymphopenia. CSS: cancer-specific survival, X2: Chi-square test, HR: Hazard Ratio, IC: confidence interval, FIGO: International Federation of Gynecology and Obstetrics, NLR: Neutrophil-to-Lymphocytes ratio, SII: Systemic Immune-Inflammatory Index, MLR: Monocyte-to-Lymphocyte ratio.